Diabetologia:年轻2型糖尿病患者的发病居然另有他因?

2021-11-12 从医路漫漫 MedSci原创

传统上,2型糖尿病被认为是一种以胰岛素抵抗和胰岛素缺乏为特征的疾病。然而,这种疾病是异质性的。

传统上,2型糖尿病被认为是一种以胰岛素抵抗和胰岛素缺乏为特征的疾病。然而,这种疾病是异质性的。瑞典的一个大队列提出了对五个不同亚组的正式描述,并在其他人群中进行了验证:重度自身免疫性糖尿病(SAID)、严重胰岛素缺乏性糖尿病(SIDD)、严重胰岛素抵抗糖尿病(SIRD)、轻度肥胖相关糖尿病(MOD)和轻度年龄相关性糖尿病(MARD)。这些亚型不仅在诊断时的临床特征上有所不同,而且在病理生理机制和对并发症的易感性上也有所不同。本研究的目的是测试这种表型在印度年轻发病的2型糖尿病患者中的适用性。

方法:我们将欧洲来源的中心体应用于来自WellGen队列的45岁前诊断为2型糖尿病的印度个体(n= 1612)。我们还应用新方法对这些亚组进行了验证。然后我们比较了这些亚组的临床和代谢内分泌特征以及并发症发生率。我们还比较了WellGen亚组与两个年轻欧洲队列的特征,ANDIS (n=962)和DIREVA(n=420)。在另外两个印度队列Ahmedabad (n=187)和PHENOEINDY-2 (n=205)中也进行了亚组评估。

WellGen研究:WellGen研究包括2004-2006年间前往KEM医院糖尿病科、浦那医院和相关诊所进行常规糖尿病治疗的患者[18]。使用世卫组织指南诊断为45岁以下糖尿病的人也包括在内[1]。2型糖尿病的诊断基于临床标准:确诊时年龄>20岁;无酮症酸中毒病史;中心性肥胖(腰臀比:女性>0.80,男性>0.90);以及口服降糖药物治疗的反应。排除临床诊断为1型糖尿病(20岁前确诊、酮症酸中毒病史、确诊后持续胰岛素治疗)、纤维结石性胰腺糖尿病(FCPD)或符合单基因糖尿病标准的个体。总共包括1612人(表1)。临床资料包括年龄、性别、糖尿病诊断年龄、家族史和社会经济状况。身高、体重、腰围、臀围和血压都是用标准化方法测量的。空腹血糖、总胆固醇、高密度脂蛋白-胆固醇、三酰甘油和糖化血红蛋白的测定采用如前所述的标准实验室分析方法。空腹C肽测定采用ELISA法(加拿大安大略省诊断生物化学公司)。空腹血糖和C肽测量用于计算稳态模型评估β细胞功能(HOMA2-B)和胰岛素抵抗(HOMA2-IR)值。记录治疗细节(胰岛素、口服降糖、降压和降脂药物)。

Ahmedabad:2018-2019年到Ahmedabad医疗诊所就诊的临床诊断为2型糖尿病的患者,年龄在45岁以下,糖尿病病程不到2年的患者得到了187人的同意。测量包括人体测量、糖化血红蛋白(HbA1)水平以及空腹血糖和C肽(MAGLUMI C肽;CLIA,中国深圳)(表1)。

PHENOEINDY-2:2017-2019年期间在迪布鲁加尔市阿萨姆医学院内科门诊部就诊的临床诊断为2型糖尿病的患者,如果被诊断为40岁以下,则被邀请参加,205人同意。测量包括人体测量、糖化血红蛋白(HbA1)水平、空腹血糖和C肽测量(ELISA,诊断生物化学加拿大,ON,加拿大)(表2)。

ANDIS:ANDIS项目包括瑞典斯堪尼亚郡2008至2016年间新诊断的18岁以上糖尿病患者。生化和人体测量以及并发症的存在被记录下来,如别处所述[2]。在目前的研究中,962名45岁之前被诊断为2型糖尿病的人被包括在内。我们排除了任何已知的1型糖尿病、单基因糖尿病和GAD抗体阳性的人(所谓的SAID),以保持与WellGen研究的一致性。诊断后约4.2年记录并发症的发生率(如前面所述[2];表2)。

DIREVA:DIREVA包括2009年至2014年在瓦萨医院区招募的5107名糖尿病患者。在目前的研究中,424名年龄在45岁以下的2型糖尿病患者被纳入其中;排除标准与ANDIS的标准相似(表3)。生化和人体测量已经在别处进行了描述。目前的研究没有包括DIREVA的治疗或并发症数据。

结果:印度和欧洲年轻发病的2型糖尿病患者主要分为重度胰岛素缺乏(SIDD)和轻度肥胖相关(MOD)亚组,重度胰岛素抵抗(SIRD)和轻度年龄相关(MARD)亚组少见。在WellGen, SIDD(53%)比MOD(38%)更常见,与欧洲的研究结果相反(瑞典26%VS68%,芬兰24%VS71%)。在Ahmedabad和PHENOEINDY-2中,SIDD的比例也高于MOD (57% vs 33%)和67% vs 23%。在印度和欧洲,SIDD亚组的特征是胰岛素缺乏和高血糖,MOD是肥胖,SIRD是严重胰岛素抵抗,MARD是轻度代谢-内分泌紊乱。在WellGen,肾病和视网膜病变在SIDD中比MOD更普遍,而后者的神经病变患病率更高。

表1 确诊年龄小于45岁的WellGen和ANDIS研究参与者的临床和生化特征

表2 按性别分层的WellGen和ANDIS研究参与者的并发症和当前治疗

图1 来自WellGen和ANDIS研究的参与者在预定义群集中的分布。(a-c)WellGen参与者分布,显示所有参与者(n=1612)(A)、男性糖尿病患者(n=902)(B)和女性糖尿病患者(n=710)(C)。(d-f)ANDIS参与者分布,显示所有参与者(n=962)(D)、男性糖尿病患者(n=567)(E)和女性糖尿病患者(n=395)(F)

表3 所有参与者以及男性和女性参与者在WellGen和ANDIS研究中登记的特征

图2 WellGen和Andis研究中的特征盒子图。诊断时年龄(a,f)、体重指数(b,g)、糖化血红蛋白(c,h)、HOMA2-B(d,i)和HOMA2-IR(e,j)在WellGen(a-e)和Andis(f-j)研究中的分布。每个方框内的中心线代表中位数,方框的上下限代表IQR。线条是第一和第二个四分位数的1.5×IQR范围内最极端的值。k-均值聚类分别针对男性和女性进行;数据分别显示为每个性别。F,女性;M,男性

表4 WellGen和ANDIS研究的治疗和并发症集合

结论:我们的数据表明,胰岛素缺乏是印度年轻人2型糖尿病的主要驱动因素,而不像欧洲年轻人中肥胖和胰岛素抵抗占主导地位。我们的结果为印度年轻人群2型糖尿病的病理生理机制和并发症易感性提供了有用的线索,并建议有必要回顾治疗策略。

原文出处:

Prasad RB,  Asplund O,  Shukla SR,et al.Subgroups of patients with young-onset type 2 diabetes in India reveal insulin deficiency as a major driver.Diabetologia 2021 Oct 23

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1761755, encodeId=f0bd1e6175545, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Nov 29 10:19:02 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639952, encodeId=a3f816399524a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jan 21 07:19:02 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070272, encodeId=3e6410e027272, content=人群的基因问题?, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a44885671, createdName=419040982, createdTime=Sun Nov 14 22:35:03 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383735, encodeId=9de61383e35b0, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Sat Nov 13 14:19:02 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475169, encodeId=cdbb14e51693f, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Nov 13 14:19:02 CST 2021, time=2021-11-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1761755, encodeId=f0bd1e6175545, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Nov 29 10:19:02 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639952, encodeId=a3f816399524a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jan 21 07:19:02 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070272, encodeId=3e6410e027272, content=人群的基因问题?, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a44885671, createdName=419040982, createdTime=Sun Nov 14 22:35:03 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383735, encodeId=9de61383e35b0, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Sat Nov 13 14:19:02 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475169, encodeId=cdbb14e51693f, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Nov 13 14:19:02 CST 2021, time=2021-11-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1761755, encodeId=f0bd1e6175545, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Nov 29 10:19:02 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639952, encodeId=a3f816399524a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jan 21 07:19:02 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070272, encodeId=3e6410e027272, content=人群的基因问题?, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a44885671, createdName=419040982, createdTime=Sun Nov 14 22:35:03 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383735, encodeId=9de61383e35b0, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Sat Nov 13 14:19:02 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475169, encodeId=cdbb14e51693f, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Nov 13 14:19:02 CST 2021, time=2021-11-13, status=1, ipAttribution=)]
    2021-11-14 419040982

    人群的基因问题?

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1761755, encodeId=f0bd1e6175545, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Nov 29 10:19:02 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639952, encodeId=a3f816399524a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jan 21 07:19:02 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070272, encodeId=3e6410e027272, content=人群的基因问题?, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a44885671, createdName=419040982, createdTime=Sun Nov 14 22:35:03 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383735, encodeId=9de61383e35b0, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Sat Nov 13 14:19:02 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475169, encodeId=cdbb14e51693f, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Nov 13 14:19:02 CST 2021, time=2021-11-13, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1761755, encodeId=f0bd1e6175545, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Nov 29 10:19:02 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639952, encodeId=a3f816399524a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jan 21 07:19:02 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070272, encodeId=3e6410e027272, content=人群的基因问题?, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a44885671, createdName=419040982, createdTime=Sun Nov 14 22:35:03 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383735, encodeId=9de61383e35b0, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Sat Nov 13 14:19:02 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475169, encodeId=cdbb14e51693f, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Nov 13 14:19:02 CST 2021, time=2021-11-13, status=1, ipAttribution=)]

相关资讯

Diabetologia:表现为非蛋白尿的肾功能不全的2型糖尿病患者的肾脏结局和全因死亡率

表现为非白蛋白尿的肾功能不全的2型糖尿病患者的肾脏结局和生活预后均比表现为非白蛋白尿的肾功能保留的患者的更差

Diabetes Obes Metab:口服沙格列汀治疗日本2型糖尿病患者的疗效和安全性

沙格列汀是一种每日口服一次的片剂,含有胰高血糖素样肽-1(GLP-1)受体激动剂(GLP-1RA),与吸收促进剂N-(8-[2-羟基苯甲酰]氨基)辛酸钠共同配制,以便于口服。

Eur Heart:肥胖和达格列净对2型糖尿病患者心血管和肾脏结局的影响

肥胖和2型糖尿病(T2DM)的发病率和患病率不断上升,是当今全球公共健康面临的最具挑战性的威胁之一。

Diabetes Obes Metab:二甲双胍单药治疗2型糖尿病和既往3期慢性肾病的疗效

二甲双胍对3期CKD (CKD3)或估计肾小球滤过率(eGFR)为30 - 59 mL/min/1.73 m2的患者是安全的。

Cardiovasc Diabetol:卡格列净对2型糖尿病和慢性心力衰竭患者N端脑钠肽前体的影响

二甲双胍长期以来被广泛应用,是治疗2型糖尿病(T2D)已确定的基础降糖药物。

OMCL:卒中前应用二甲双胍对2型糖尿病脑出血患者1年预后的影响

二甲双胍是治疗2型糖尿病的一线药物。它可以预防糖尿病并发症。最近的研究已经证实二甲双胍具有抗氧化作用。